NASDAQ:CBMX - CombiMatrix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.25 0.00 (0.00 %)
(As of 06/22/2018 05:03 AM ET)
Previous Close$6.25
Today's Range$6.25 - $6.25
52-Week Range$2.20 - $8.20
VolumeN/A
Average Volume119,111 shs
Market Capitalization$18.40 million
P/E RatioN/A
Dividend YieldN/A
Beta0.85
CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. It performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis, fluorescence in situ hybridization and karyotyping. Its prenatal and postnatal microarray focuses on diagnosing genomic syndromes associated with intellectual disability, developmental delays, congenital anomalies, dysmorphic features and autism spectrum disorders. It develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (products of conception analysis), prenatal genetics and postnatal developmental disorders.

Receive CBMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CBMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:CBMX
CUSIPN/A
Phone+1-949-7530624

Debt

Debt-to-Equity Ratio0.02
Current Ratio3.23
Quick Ratio3.03

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.87 million
Price / Sales1.43
Cash FlowN/A
Price / CashN/A
Book Value$1.79 per share
Price / Book3.49

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-4,140,000.00
Net Margins-15.20%
Return on Equity-43.59%
Return on Assets-30.86%

Miscellaneous

Employees55
Outstanding Shares2,940,000

CombiMatrix (NASDAQ:CBMX) Frequently Asked Questions

What is CombiMatrix's stock symbol?

CombiMatrix trades on the NASDAQ under the ticker symbol "CBMX."

When did CombiMatrix's stock split? How did CombiMatrix's stock split work?

Shares of CombiMatrix reverse split on Monday, February 1st 2016. The 1-15 reverse split was announced on Wednesday, January 27th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 29th 2016. An investor that had 100 shares of CombiMatrix stock prior to the reverse split would have 7 shares after the split.

How were CombiMatrix's earnings last quarter?

CombiMatrix Corp (NASDAQ:CBMX) announced its quarterly earnings results on Monday, November, 6th. The medical research company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. The medical research company had revenue of $4.01 million for the quarter, compared to the consensus estimate of $4.19 million. CombiMatrix had a negative return on equity of 43.59% and a negative net margin of 15.20%. During the same quarter in the previous year, the business posted ($0.38) earnings per share. View CombiMatrix's Earnings History.

What price target have analysts set for CBMX?

2 Wall Street analysts have issued twelve-month price targets for CombiMatrix's stock. Their forecasts range from $8.10 to $8.10. On average, they anticipate CombiMatrix's share price to reach $8.10 in the next year. View Analyst Ratings for CombiMatrix.

Who are CombiMatrix's key executives?

CombiMatrix's management team includes the folowing people:
  • Robert Judd Jessup, Chairman of the Board (Age 68)
  • Mark McDonough, President, Chief Executive Officer, Director (Age 46)
  • Scott R. Burell, Chief Financial Officer, Treasurer, Secretary (Age 52)
  • Dirk van den Boom Ph.D., Director (Age 47)
  • Robert E. Hoffman, Independent Director (Age 51)
  • Jeremy M. Jones, Independent Director (Age 75)
  • Lale White, Independent Director (Age 60)

Has CombiMatrix been receiving favorable news coverage?

Media headlines about CBMX stock have trended positive this week, Accern reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CombiMatrix earned a news sentiment score of 0.31 on Accern's scale. They also assigned news articles about the medical research company an impact score of 45.44 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of CombiMatrix?

Shares of CBMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CombiMatrix's stock price today?

One share of CBMX stock can currently be purchased for approximately $6.25.

How big of a company is CombiMatrix?

CombiMatrix has a market capitalization of $18.40 million and generates $12.87 million in revenue each year. CombiMatrix employs 55 workers across the globe.

How can I contact CombiMatrix?

CombiMatrix's mailing address is 310 Goddard Ste 150, IRVINE, CA 92618-4617, United States. The medical research company can be reached via phone at +1-949-7530624.


MarketBeat Community Rating for CombiMatrix (CBMX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  132
MarketBeat's community ratings are surveys of what our community members think about CombiMatrix and other stocks. Vote "Outperform" if you believe CBMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.